Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial

Autor: Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Christopher D Brawley, Simon Chowdhury, William Cross, David P Dearnaley, Duncan C Gilbert, Silke Gillessen, Robert J Jones, Ruth E Langley, Archie Macnair, Zafar I Malik, Malcolm D Mason, David J Matheson, Robin Millman, Chris C Parker, Hannah L Rush, J Martin Russell, Carly Au, Alastair W S Ritchie, Ricardo Pereira Mestre, Imtiaz Ahmed, Alison J Birtle, Susannah J Brock, Prantik Das, Victoria A Ford, Emma K Gray, Robert J Hughes, Caroline B Manetta, Duncan B McLaren, Ashok D Nikapota, Joe M O’Sullivan, Carla Perna, Clive Peedell, Andrew S Protheroe, Santhanam Sundar, Jacob S Tanguay, Shaun P Tolan, John Wagstaff, Jan B Wallace, James P Wylie, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes

Publikováno v: James, N D, Ingleby, F C, Clarke, N W, Amos, C L, Attard, G, Brawley, C D, Chowdhury, S, Cross, W, Dearnaley, D P, Gilbert, D C, Gillessen, S, Jones, R J, Langley, R E, Macnair, A, Malik, Z I, Mason, M D, Matheson, D J, Millman, R, Parker, C C, Rush, H L, Russell, J M, Au, C, Ritchie, A W S, Mestre, R P, Ahmed, I, Birtle, A J, Brock, S J, Das, P, Ford, V A, Gray, E K, Hughes, R J, Manetta, C B, McLaren, D B, Nikapota, A D, O'Sullivan, J M, Perna, C, Peedell, C, Protheroe, A S, Sundar, S, Tanguay, J S, Tolan, S P, Wagstaff, J, Wallace, J B, Wylie, J P, Zarkar, A, Parmar, M K B & Sydes, M R 2022, ' Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial ', JNCI Cancer Spectrum, vol. 6, no. 4, pkac043 . https://doi.org/10.1093/jncics/pkac043

Background STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00eff5f0fa14f1899d76357eb1c4d2a4
https://eprints.gla.ac.uk/276500/1/276500.pdf

RAMPART : a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Autor: Laurence Albiges, Martin R. Stockler, Grant D. Stewart, Alastair W. S. Ritchie, Sarah Scovell, Tim Eisen, Salena Mulhere, Mahesh K. B. Parmar, Ben Smith, Brian I. Rini, David J. Harrison, Richard Kaplan, Thomas Powles, Nat Thorogood, Hanna Bryant, Anita McWhirter, Bhavna Oza, Alison Fielding, James Larkin, Angela M. Meade, Axel Bex, Ian D. Davis, Clare Shakeshaft, Babak Choodari-Oskooei, Paul Nathan, Eleni Frangou, Toni K. Choueiri

Publikováno v: Contemporary Clinical Trials

Background 20–60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b398c819f256a4095399e1c7d91222e7
https://hdl.handle.net/10023/23999

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Autor: Malcolm David Mason, Robin Millman, Alison Birtle, Duncan McLaren, David Matheson, Stephanie Gibbs, John Graham, Prabir Chakraborti, Mahesh K. B. Parmar, Joanna Gale, Matthew S. Simms, Melissa Gannon, John Wagstaff, Anna T.H. Tran, J. Martin Russell, Robert Hughes, Joe M. O'Sullivan, Santhanam Sundar, Omi Parikh, Beth Woods, Mymoona Alzouebi, Audrey Cook, Richard Cathomas, Angus Robinson, Eleftherios Sideris, Robert Jones, Robert W. Laing, Susannah Brock, Clive Peedell, Narayanan Srihari, Chris Parker, Shaun Tolan, Gerhardt Attard, Nicholas D. James, Matthew R. Sydes, Alastair W. S. Ritchie, Andrew Protheroe, Mark Sculpher, William Cross, David Tsang, George N. Thalmann, Rajaguru Srinivasan, John Staffurth, David P. Dearnaley

Publikováno v: Woods, B S, Sideris, E, Sydes, M R, Gannon, M R, Parmar, M K B, Alzouebi, M, Attard, G, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P R, Cook, A, Cross, W R, Dearnaley, D P, Gale, J, Gibbs, S, Graham, J D, Hughes, R, Jones, R J, Laing, R, Mason, M D, Matheson, D, McLaren, D B, Millman, R, O'Sullivan, J M, Parikh, O, Parker, C C, Peedell, C, Protheroe, A, Ritchie, A W S, Robinson, A, Russell, J M, Simms, M S, Srihari, N N, Srinivasan, R, Staffurth, J N, Sundar, S, Thalmann, G N, Tolan, S, Tran, A T H, Tsang, D, Wagstaff, J, James, N D & Sculpher, M J 2018, ' Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness ', European urology oncology, vol. 1, no. 6, pp. 449-458 . https://doi.org/10.1016/j.euo.2018.06.004
European Urology Oncology

Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs fai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2281fcf0ea5be2ac6317f225090278
https://doi.org/10.1016/j.euo.2018.06.004

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

Autor: Nicholas D, James, Matthew R, Sydes, Malcolm D, Mason, Noel W, Clarke, John, Anderson, David P, Dearnaley, John, Dwyer, Gordana, Jovic, Alastair W S, Ritchie, J Martin, Russell, Karen, Sanders, George N, Thalmann, Gianfilippo, Bertelli, Alison J, Birtle, Joe M, O'Sullivan, Andrew, Protheroe, Denise, Sheehan, Narayanan, Srihari, Mahesh K B, Parmar, Razvan, Popescu

Publikováno v: The Lancet Oncology. 13:549-558

Summary Background Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage design to assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6146da7f65380784acf2add5b565303
https://doi.org/10.1016/s1470-2045(12)70088-8

The influence of histological diagnosis on the postoperative complication rate following trans-urethral resection of prostate (TURP)

Autor: A W S Ritchie, H W Gilbert, D J Jones, P Crow

Publikováno v: Annals of the Royal College of Surgeons. 84:418-421

BACKGROUND: A number of studies have shown that the early mortality following TURP is higher for patients with prostate cancer than those with benign disease. This study examines the effect of the histological diagnosis on the predischarge complicati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e2ec634af2302c23134a7fc231ce40
https://doi.org/10.1308/003588402760978238